With CTLA-4-inhibitor therapy, colitis, hepatitis, and pneumonitis are predominant, and in anti-PD-1/PD-L1 regimens, pneumonitis, hepatitis, colitis, neurological events, and myocarditis are relatively common. This evidence concerns the gene CD274 and hepatitis A virus infection.